QUARTER 2, MODULE 3 & 4

WHAT I CAN DO

MY FUTURE RESEARCH

MY TABULATED RRL

Title, Author Other details Related and Related and Related and Other related
and date about the relevant data: relevant data: relevant data and relevant
source RESULTS and CONCLUSIONS RECOMMEN- data
FINDINGS DATIONS
Covid-19 PLOS Global Vaccines were Challenges to There is a need Provide
vaccine brand Public Health viewed by as covid to study best technological
hesitancy and 2(1): e0000165. unnecessary by vaccination practices in support
other https://doi.org/ some maybe vaccine rollout particularly
challenges to 10.371./journal. participants, individual, to implement among older
vaccination in pgph.0000165 especially those interpersonal, systems that populations and
the Philippines; in older age and/or are efficient and allow flexible
Amit, Arianna groups who are structural, which inclusive so that options for
Maever L., not allowed to interact to we can receiving the
Dayrit, Manuel go out. Those influence vaccinate as vaccines such as
M., Pepito, in the lower decisions. many people home
Veincent priority groups Individual against Covid- vaccination.
Christian F., felt that other perceptions play 19 as quickly Given resource
Tanchanco, needed the a major role in and as limitations, the
Lourdes S.; vaccine more the decision to inclusively as vaccination
2022 than them. vaccinate and possible. rollout could
Younger such also be
participants perceptions are improved by
shared that shaped by increasing the
they were exposure to role of the
covid-19 (mis)information private sector in
survivors even amplified by the the rollout
without the media, the administration
vaccine; but community and of the vaccine.
those at high the health The
risk especially system in the government
the elderly and country. and health
persons with organizations
comorbidities will need to
will need the connect with
vaccine to individuals,
protect them. communities
and other
institutions to
co-create
effective and
sustainable
solutions.
 Covid-19 National Library Data gathered The analysis of Due to the short Technical
vaccines: where of Medicine, suggest that preferences for development problems
we stand and National Center new vaccine different time and the connected with
challenges for candidates may hypothetical novelty of the the production
ahead; Biotechnology be instrumental vaccines technologies of billions of
Forni, Guido, Information. in protecting indicates that adopted, these doses and
Mantovani, COVID-19 individuals and people value a vaccines will be ethical ones
Alberto. Commission of reducing the vaccine's minor deployed with connected with
2021 Accademia spread of side effects several the availably of
Nazionale dei pandemic. The more than its unresolved these vaccines
Lincei, Rome conceptual and effectiveness. issues that only also in the
https://pubmed. technological This provides the passage of poorest
ncbi.nlm.nih. platforms evidence time will permit countries, are
gov/33479399/ exploited are regarding the to clarify. imminent
diverse, and it is importance of challenges
likely that rigorous human facing us. It is
different testing for any our tenet that
vaccines will vaccine, and the in the long run
show to be significance of more than one
better suited to communication vaccine will be
distinct groups with society needed to
of the human regarding its ensure
population. side effects. equitable global
Collectively, access,
these will protection of
directly affect diverse subjects
individuals' and immunity
vaccination against viral
preferences and variants.
decisions.
B. WORKING REFERENCE LIST OF THE RESEARCH PROPOSAL.

1. Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health

emergency. Sci Total Environ. (2020) 730:138996. doi: 10.1016/j.scitotenv.2020.138996

2. Koon OE. The impact of sociocultural influences on the COVID-19 measures—reflections from Singapore. J

Pain Symptom Manag. (2020) 60:e90–e2. doi: 10.1016/j.jpainsymman.2020.04.022

3. Torales J, O'Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19: coronavirus and its

impact on global mental health. Int J Soc Psychiatry. (2020) 66:317–20. doi: 10.1177/0020764020915212

4. García LY, Cerda AA. Contingent assessment of the COVID-19 vaccine. Vaccine. (2020) 38:5424–9. doi:

10.1016/j.vaccine.2020.06.068

5. Wong LP, Alias H, Wong P-F, Lee HY, AbuBakar S. The use of the health belief model to assess predictors of

intent to receive the COVID-19 vaccine and willingness to pay. Hum Vaccines Immunother. (2020) 16:1–11.

doi: 10.1080/21645515.2020.1790279

6. Jones CL, Jensen JD, Scherr CL, Brown NR, Christy K, Weaver J. The health belief model as an explanatory

framework in communication research: exploring parallel, serial, and moderated mediation. Health

Commun. (2015) 30:566–76. doi: 10.1080/10410236.2013.873363

7. Gianfredi V, Moretti M, Lopalco PL. Countering vaccine hesitancy through immunization information

systems, a narrative review. Human Vacci Immunother. (2019) 15(11):2508–26. doi:

10.1080/21645515.2019.1599675

8. Henderson J, Ward PR, Tonkin E, Meyer SB, Pillen H, McCullum D, et al. Developing and maintaining public

trust during and post-COVID-19: can we apply a model developed for responding to food scares? Front

Public Health. (2020) 8:369. doi: 10.3389/fpubh.2020.00369

9. Ward PR, Attwell K, Meyer SB, Rokkas P, Leask J. Risk, responsibility and negative responses: a qualitative

study of parental trust in childhood vaccinations. J Risk Res. (2018) 21:1117–30. doi:

10.1080/13669877.2017.1391318

10. The Economist. Conspiracy Theories About Covid-19 Vaccines May Prevent Herd Immunity. The Economist

(2020).